These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: [New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates]. Author: Okazaki R. Journal: Clin Calcium; 2009 Jan; 19(1):30-6. PubMed ID: 19122262. Abstract: Despite widely accepted efficacy of bisphophonates for osteoporotic fracture, patients treatment compliance has been low, especially, with daily regimen, in part because of the inconvenience associated with special dosing requirements of oral bisphophonates. Intermittent bisphophonates, oral and intravenous, have been introduced to solve the problem. In Japan, at present, only weekly alendronate and risedronate, both oral, have been approved for osteoporosis. In U. S. A. and other countries, orally, monthly risedoronate and ibandronate, intravenously, quarterly ibandronate and yearly zoledronate have been approved for osteoporosis. Their clinical efficacy will be reviewed.[Abstract] [Full Text] [Related] [New Search]